NARCISO BARRIOS: Open Payments
NPI 1528783230 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$946 in 45 payments from 14 companies in 2025. Trend: 2023 $1,079 · 2024 $1,191 · 2025 $946
Food & beverage: $925Education: $21
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 4 | $190 |
| Novartis Pharmaceuticals Corporation | 12 | $169 |
| Ardelyx, Inc. | 3 | $117 |
| Mallinckrodt Hospital Products Inc. | 4 | $80 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $71 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $56 |
| Vifor Pharma, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $36 |
| Travere Therapeutics, Inc. | 3 | $36 |
Products named: TARPEYO, JARDIANCE, Vanrafia, Fabhalta, XPHOZAH 30 MG, ACTHAR, FARXIGA, Kerendia.
Industry payments across DE — which companies pay providers there.
